AFFITOPE® PD01A — Competitive Intelligence Brief

AFFITOPE® PD01A (AFFITOPE® PD01A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: peptide. Area: Neurology.

phase 1 peptide alpha-synuclein Neurology Biologic

Target snapshot

AFFITOPE® PD01A (AFFITOPE® PD01A) — Affiris AG. AFFITOPE® PD01A is designed to induce an immune response against alpha-synuclein, a protein implicated in Parkinson's disease.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AFFITOPE® PD01A TARGET	AFFITOPE® PD01A	Affiris AG	phase 1	peptide	alpha-synuclein
Destriol	ESTRIOL		marketed	estriol	Corticosteroid-binding globulin, Olfactory receptor 51E2, Alpha-synuclein	2000-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	marketed	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Menadion	MENADIONE	Eli Lilly	marketed	Vitamin D [EPC]	Aldehyde oxidase, Alpha-synuclein, Dual specificity phosphatase Cdc25A	1982-01-01
Rifadin	Rifampicin	Sanofi Aventis Us	marketed	Rifamycin Antibacterial [EPC]	Solute carrier organic anion transporter family member 1A2, ATP-binding cassette sub-family G member 2, Alpha-synuclein	1971-01-01
Zelapar	Zelapar	Baylor College of Medicine	marketed		Alpha-synuclein, Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor
Bromocriptin	Bromocriptin	University Hospital, Bonn	marketed		5-hydroxytryptamine receptor 6, Alpha-synuclein, D(1B) dopamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (peptide class)

1. Affiris AG · 1 drug in this class